Therapeutic landscape and future direction of metastatic colorectal cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic landscape and future direction of metastatic colorectal cancer
Authors
Keywords
-
Journal
Nature Reviews Gastroenterology & Hepatology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-21
DOI
10.1038/s41575-022-00736-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability‐high/mismatch repair‐deficient or POLE ‐mutated metastatic or unresectable colorectal cancer
- (2022) Chung Ryul Oh et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8.
- (2022) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.
- (2022) Romain Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).
- (2022) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
- (2022) Debyani Chakravarty et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.
- (2022) Van K. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
- (2022) Emerik Osterlund et al. Frontiers in Oncology
- Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer
- (2022) Niharika B. Mettu et al. JAMA Network Open
- Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
- (2022) Federica Morano et al. JOURNAL OF CLINICAL ONCOLOGY
- Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2022) Carlotta Antoniotti et al. LANCET ONCOLOGY
- Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
- (2022) Luis A Diaz et al. LANCET ONCOLOGY
- Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
- (2022) Giovanni Crisafulli et al. Cancer Discovery
- The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection
- (2022) Swati G Patel et al. Lancet Gastroenterology & Hepatology
- LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
- (2022) A. Bullock et al. ANNALS OF ONCOLOGY
- O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials
- (2022) E. Martinelli et al. ANNALS OF ONCOLOGY
- LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC
- (2022) J. Strickler et al. ANNALS OF ONCOLOGY
- P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
- (2022) A. Hendifar et al. ANNALS OF ONCOLOGY
- Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)
- (2022) Jiarui Li et al. EUROPEAN JOURNAL OF CANCER
- Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC).
- (2022) Andrew Eugene Hendifar et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
- (2022) Yoshinori Kagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
- (2022) Takayuki Yoshino et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to epithelial growth factor receptor inhibitor (EGFRi) treatment in patients with early-onset, treatment-naïve metastatic colorectal cancer (mCRC): An ARCAD database analysis.
- (2022) Zhaohui Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
- (2022) Andrea Sartore-Bianchi et al. NATURE MEDICINE
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
- (2022) A. Cervantes et al. ANNALS OF ONCOLOGY
- Trajectory for the regulatory approval of a combination of pertuzumab plus trastuzumab for pre-treated HER2-positive metastatic colorectal cancer using real-world data
- (2022) Yasutoshi Sakamoto et al. Clinical Colorectal Cancer
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- (2022) Van K. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
- (2022) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
- (2021) Thierry Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.
- (2021) Carlos Gomez-Roca et al. JOURNAL OF CLINICAL ONCOLOGY
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
- (2021) Jiali Yu et al. NATURE MEDICINE
- Cabozantinib and Panitumumab for RAS Wild‐Type Metastatic Colorectal Cancer
- (2021) John H. Strickler et al. ONCOLOGIST
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
- (2021) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
- (2021) Arta M. Monjazeb et al. CLINICAL CANCER RESEARCH
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2021) Al B. Benson et al. Journal of the National Comprehensive Cancer Network
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Artificial intelligence for clinical oncology
- (2021) Benjamin H. Kann et al. CANCER CELL
- CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
- (2021) Hiroya Taniguchi et al. CANCER SCIENCE
- Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
- (2021) Salvatore Siena et al. LANCET ONCOLOGY
- The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
- (2021) Benoit Rousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation
- (2021) Noritaka Tanaka et al. Cancer Discovery
- O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer
- (2021) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- 506TiP Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study
- (2021) T. Yoshino et al. ANNALS OF ONCOLOGY
- LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
- (2021) C. Cremolini et al. ANNALS OF ONCOLOGY
- 386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
- (2021) S. Siena et al. ANNALS OF ONCOLOGY
- REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
- (2021) Hiromichi Nakajima et al. BMC CANCER
- SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors
- (2021) Yoshiaki Nakamura et al. CANCER SCIENCE
- Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
- (2021) Roberto Moretto et al. Clinical Colorectal Cancer
- Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
- (2021) Sebastian Stintzing et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
- (2021) Kanwal Pratap Singh Raghav et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.
- (2021) Ying Yuan et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
- (2021) Keigo Chida et al. ONCOLOGIST
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer
- (2021) Erika Martinelli et al. JAMA Oncology
- Artificial intelligence in oncology: current applications and future perspectives
- (2021) Claudio Luchini et al. BRITISH JOURNAL OF CANCER
- Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
- (2021) Jenny F. Seligmann et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
- (2021) Yoshiaki Nakamura et al. NATURE MEDICINE
- Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.
- (2020) Ranju Gupta et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
- (2020) Eyal Meiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions
- (2020) T. Yoshino et al. ANNALS OF ONCOLOGY
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer
- (2020) Andrea Sartore-Bianchi et al. JAMA Oncology
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
- (2020) R. Corcoran et al. ANNALS OF ONCOLOGY
- Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial)
- (2020) Akihito Kawazoe et al. CLINICAL CANCER RESEARCH
- Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer
- (2020) Federica Tosi et al. Clinical Colorectal Cancer
- Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
- (2020) Toshiki Masuishi et al. BRITISH JOURNAL OF CANCER
- Epidemiology and Molecular- Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer
- (2020) Shailesh M. Advani et al. Clinical Colorectal Cancer
- Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
- (2020) Chiara Cremolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
- (2020) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
- (2020) Andrea Sartore-Bianchi et al. ESMO Open
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
- (2020) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials
- (2020) Romain Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions
- (2019) Emiliano Cocco et al. CANCER RESEARCH
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
- (2019) Funda Meric-Bernstam et al. LANCET ONCOLOGY
- HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer
- (2019) Andrea Sartore‐Bianchi et al. ONCOLOGIST
- Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
- (2019) J Taieb et al. ANNALS OF ONCOLOGY
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer
- (2019) Charalampos S. Floudas et al. Clinical Colorectal Cancer
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- 527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
- (2019) J H Strickler et al. ANNALS OF ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive mutability of colorectal cancers in response to targeted therapies
- (2019) Mariangela Russo et al. SCIENCE
- Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population
- (2019) Jianfei Yao et al. Scientific Reports
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
- (2018) F Pietrantonio et al. ANNALS OF ONCOLOGY
- Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
- (2018) Kentaro Sawada et al. Clinical Colorectal Cancer
- MODUL—a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach
- (2018) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers
- (2018) Hiroshi Kotani et al. ONCOGENE
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
- (2018) Clara Montagut et al. JAMA Oncology
- Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy
- (2018) Aziz Zaanan et al. JAMA Oncology
- International harmonization of diagnostic criteria for HER2-amplified metastatic colorectal cancer and application of targeted next-generation sequencing panel as a diagnostic method.
- (2018) Satoshi Fujii et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.
- (2018) Kanwal Pratap Singh Raghav et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- (2018) C M Parseghian et al. ANNALS OF ONCOLOGY
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- (2018) Alicia Latham et al. JOURNAL OF CLINICAL ONCOLOGY
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
- (2017) Laetitia Nebot-Bral et al. EUROPEAN JOURNAL OF CANCER
- CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
- (2017) Hege Marie Vedeld et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer
- (2017) Alan P. Venook et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Colon Cancer
- (2017) Paul F. Engstrom et al. Journal of the National Comprehensive Cancer Network
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
- (2016) D. P. Modest et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
- (2016) Susan D Richman et al. JOURNAL OF PATHOLOGY
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
- (2016) Kanwal Raghav et al. Oncotarget
- Patterns of metastasis in colon and rectal cancer
- (2016) Matias Riihimäki et al. Scientific Reports
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
- (2015) X. Liu et al. BMC CANCER
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
- (2015) R. Yaeger et al. CLINICAL CANCER RESEARCH
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2/neu testing in primary colorectal carcinoma
- (2014) B Ingold Heppner et al. BRITISH JOURNAL OF CANCER
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2014) Dong Chen et al. PLoS One
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
- (2013) F. Pietrantonio et al. ANNALS OF ONCOLOGY
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
- (2009) T. S. Bekaii-Saab et al. MOLECULAR CANCER THERAPEUTICS
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now